Blog

Multinational pharmaceutical companies are unable to assure Australians they are not being "ripped off" on the price of medicines as ...

The May 2015 issue of the New Zealand Pharmaceutical Schedule is out and now in effect. The Schedule includes the following new/revised entry: ...

Kalydeco and Soliris – new treatments for cystic fibrosis and aHUS respectively – will be listed on the Pharmaceutical Benefits ...

Additional Public Summary Documents (PSDs) from the November 2014 Pharmaceutical Benefits Advisory Committee meeting are now available on the PBS website. The links ...

[:content [\2 \1 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \space \T \h \e \space \l \i \n \k \s \space \t \o \space \t \h \e \space \P \u \b \l \i \c \space \S \u \m \m \a \r \y \space \D \o \c \u \m \e \n \t \s \space \f \o \r \space \t \h \e \space \i \n \i \t \i \a \l \space \r \e \j \e \c \t \i \o \n \s \space \f \r \o \m \  \t \h \e \space \P \B \A \C \space \m \e \e \t \i \n \g \space \h \e \l \d \space \i \n " ..."]]

[:content [\2 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \G \e \r \m \a \n \space \l \e \g \i \s \l \a \t \o \r \s \space \h \a \v \e \space \v \o \t \e \d \space \t \o \space \c \o \n \t \i \n \u \e \space \u \n \t \i \l \space \t \h \e \space \e \n \d \space \o \f \space \2 \0 \1 \7 \space \t \h \e \space \p \r \i \c \e \space \f \r \e \e \z \e \space \o \n \space \r \e \i \m \b \u \r \s \e \d \space \d \r \u \g \s " ..."]]

Canada’s two-tiered process of approving potentially life-saving oncology drugs is preventing cancer patients in some provinces from accessing medication that’s ...

CADTH invites all interested parties to provide feedback on the draft Guidelines for Manufacturers on Application Fees for the pan-Canadian Oncology Drug Review. The ...

CADTH has received a drug submission from Boehringer Ingelheim for Spiriva Respimat (tiotropium bromide monohydrate). ...

Cost regulators for the National Health Service in England have asked for more information on the use of Novartis’ asthma ...

PHARMAC is pleased to announce the following changes to the funding access criteria for a number of vaccines. The changes ...

When CADTH’s first Call for Patient Input was issued in May 2010, three patient groups answered: Arthritis Consumer Experts, Canadian ...

[:content [\1 \1 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \  \T \h \e \space \S \M \C \space \a \d \v \i \c \e \space \f \o \r \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \h \a \s \space \b \e \e \n \space \e \n \t \e \r \e \d \space \i \n \t \o \space \M \A \E \S \T \r \O \space \S \c \o \t \l \a \n \d \. " ..."]]

[:content [\N \o \t \e \space \t \h \e \space \P \u \b \l \i \c \space \S \u \m \m \a \r \y \space \D \o \c \u \m \e \n \t \s \space \f \o \r \space \a \f \a \t \i \n \i \b \space \d \i \m \a \l \e \a \t \e \space \( \G \i \o \t \r \i \f \/ \T \o \m \t \o \v \o \k \) \; \space \t \h \e \space \o \u \t \c \o \m \e \s \space \f \o \r \space \t \h \e \space \t \w \o \space \s \u \b \m \i \s \s \i \o \n \s \space \f \r \o \m \space \B \o \e \h \r \i \n \g \e \r \space \I \n \g \e \l \h \e \i \m \space \t \h \a \t \space \w \e \r \e " ..."]]